Drug Profile
Rotigotine extended release - Luye Pharma Group
Alternative Names: LY-03003; LY-03009; Rotigotine extended releaseLatest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator Luye Pharma Group
- Class Antiparkinsonians; Small molecules; Tetrahydronaphthalenes; Thiophenes
- Mechanism of Action Dopamine D2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Parkinson's disease
- Phase I Restless legs syndrome
Most Recent Events
- 28 Nov 2023 Phase-II clinical trials in Parkinson's disease in Japan (IM), prior to November 2023 (Luye Pharma Group pipeline, November 2023)
- 07 Aug 2023 LY 03003 is still in phase I trials for Parkinson's Disease in Japan
- 01 Aug 2023 Preregistration for Parkinson's disease in China (IM, Controlled-release)